Gyre Therapeutics (GYRE) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Rezolute (RZLT) over the past year, losing 44.2% versus a loss of 60.1%. Over five years, RZLT leads with a -26.9% price change compared with -77.5% for GYRE. Rezolute is the larger company by market cap ($465.6 million vs $460.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | RZLT |
|---|---|---|
| Share price | $4.21 | $3.92 |
| Market cap | $460.79M | $465.58M |
| 1-day change | -6.86% | -6.67% |
| YTD return | -40.37% | +66.10% |
| 1-year return | -44.24% | -60.12% |
| 5-year return | -77.55% | -26.87% |
| Forward P/E | 70.17 | — |
| EPS (TTM) | $-0.31 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $116.59M | — |
| Revenue growth (YoY) | +10.24% | — |
| Net income (latest FY) | $9.88M | $-77.60M |
| Gross margin | 95.35% | — |
| Operating margin | 9.85% | — |
| Net margin | 8.47% | — |
| 52-week high | $9.14 | $11.17 |
| 52-week low | $3.97 | $1.07 |
| Distance from 52-week high | -53.94% | -64.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +343.47% | +175.51% |
| Average volume | 181.04K | 1.66M |
| Shares outstanding | 109.45M | 118.77M |
| Employees | 625 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed RZLT by 15.9 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
GYRE vs RZLT FAQ
Which is bigger, Gyre Therapeutics or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $465.58M compared with $460.79M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GYRE or RZLT?
GYRE returned -44.24% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.